Author: Saral, Gulsah ; Ay, Serhan ; Selcuk, Murat ; Schuler, Gerhard ; Fontaine, Christelle Speiser ; Findik, Murat ; Vasetska, Anastasiia ; Binli, Firdevs ; Pilgram, Caroline ; Goericke-Pesch, Sandra ; Körber, Hanna ; Aslan, Selim ; Akal, Eser

01 Aug 2023·Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere

The use of a 4.7 mg deslorelin slow release implant in male dogs in the field

Article

Abstract Objective Slow-release GnRH agonist implants (SRI) are used for reversible medical downregulation of testicular function in male dogs as an alternative to surgery. The 4.7 mg deslorelin SRI should reduce testosterone after 6–8 weeks and induce castration-like effects for 6 months (mon). However, some individual variation is described in the field in regard to onset and duration of effect. For this reason, we aimed to study the effects of the 4.7 mg deslorelin SRI in a larger cohort. Material and methods In total 50 intact, healthy male dogs (12–48 months, mon; 9–40 kg) were treated with a 4.7 mg deslorelin SRI into the umbilical area (TG, n=45) or served as untreated controls (CG, n=5). CG dogs were surgically castrated after measurement of testicular dimensions and blood sampling for testosterone. In TG, SRIs remained for 5 mon in place and subsequently 3–7 male dogs were surgically castrated at removal (week, W 0) or 1, 2, 3, 4, 5, 6, 7, 8 or 10 weeks later. Examination parameters were testicular dimensions (before treatment, at 4, 8, 12 W, 5 mon, weekly until castration), testosterone (before treatment, at 8 W, 5 mon, castration) and testicular histology (castration). Results Whereas examination parameters did not differ between CG and TG before treatment, testicular volume and testosterone was significantly reduced at all time points during treatment. In all but 3 (8 W) and 2 male dogs (5 mon) testosterone was basal during treatment before removal, whereas the parameters were significantly reduced compared to pre-treatment in the respective dogs. After implant removal, testosterone and testicular volumes increased. However, different to earlier studies, the „restart“ was more variable with individual basal testosterone until W7, but also physiological testosterone concentrations in W2. Similarly, histological testicular findings at castration were quite variable: besides an arrest on spermatogonia and spermatocytes, elongated spermatids with normal spermatogenesis were found in individual dogs. Conclusion Our study confirms the efficacy of the deslorelin SRI, but also individual variation especially regarding reversibility of effects on endocrine and germinative testicular function. Clinical relevance Deslorelin SRIs offer a suitable alternative to surgical castration with individual variation to be considered when used in clinical practice.

01 Aug 2022·The Veterinary Journal

The effect of pre-calving injection of trace mineral supplements on periparturient disease incidence in pasture based dairy cows

Article

Author: Laven, R A ; Wells, M ; Bates, A J

Trace minerals, have a role in immune function and a trace mineral supplement (TMS) can improve animal health in dairy herds. This prospective randomised clinical study assessed whether subcutaneous injection of 5.5 mL of TMS (40 mg zinc, 10 mg manganese, 5 mg selenium, 15 mg copper per mL), 14-28 days before planned start of calving (PSC) reduced clinical mastitis (CM), subclinical mastitis (SCM) and purulent vaginal discharge (PVD). From four farms, half of 1700 cows stratified on somatic cell count, age and breed were randomly allocated to treatment or no treatment. Occurrence of CM from - 7 to PSC + 100 days, SCM at PSC + 60 days and PVD at PSC + 24 days was analysed using survival analysis and Bayesian generalised mixed multivariable models. From -7 to PSC +30 days, TMS reduced the adjusted hazard ratio (HR) for CM at quarter and cow level (P < 0.001), with no evidence for an effect beyond 30 days. The adjusted OR (and 95% highest density interval, HDI) for the effect of TMS on CM from -7 to PSC +30 days was 0.40 (95% HDI, 0.26-0.63) at quarter level, 0.51 (95% HDI, 0.38-0.69) at cow level and for SCM, 0.72 (95% HDI, 0.54-0.95). The difference in CM incidence from TMS at the cow level was -2.0% (95% HDI, -3.4 to -1.1%) and -1.2% (95% HDI, -3.2 to - 0.6%) at quarter level. No clear effect was identified of TMS on cumulative incidence of PVD.

News (Medical) associated with Virbac SA

11 Jul 2024

·www.globenewswire.com

Virbac: Termination of the liquidity contract

TERMINATION OF THE LIQUIDITY CONTRACT We inform you of the termination of our liquidity contract since July 1st, 2024. This contact was in place since February 19, 2019 and suspended since February 3rd, 2023. A lifelong commitment to animal healthAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and to shaping the future of animal health together. Virbac: Euronext Paris - subfund A – ISIN code: FR0000031577 / MNEMO: VIRPFinancial Affairs Department: tel. 04 92 08 71 32 - email: finances@virbac.com - Website: corporate.virbac.com Attachment Virbac_termination_of_the_liquidity_contract_01 07 2024

02 Jul 2024

·www.globenewswire.com

Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialist

On June 21, we finalized the acquisition of Globion's minority shares, bringing our stake to 100%. As planned, this transaction follows the acquisition of a 74% majority stake concluded on November 1, 2023. Founded in 2005, as a joint venture between Suguna Group, one of the leading Indian poultry conglomerates, and Lohmann Animal Health, a German poultry vaccines specialist, Globion has developed robust know-how and expertise in the development, manufacturing and commercialization of live and inactivated vaccines targeting a large array of avian pathogens. Globion is based in Hyderabad where its industrial and R&D facilities employ around 120 full-time employees and generated approximately €12 million of revenue in 2023. A lifelong commitment to animal healthAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and to shaping the future of animal health together. Contacts presse - Agence Libre MullenloweKeïsha Tema – k.tema@libremullenlowe.fr – 07 63 18 59 03Anne Da Silva Passos – a.dasilvapassos@libremullenlowe.fr – 07 60 53 99 28 Attachment VIRBAC PR - Finalization of the Globion acquisition- 02 07 2024

AcquisitionVaccine

02 Apr 2024

·www.globenewswire.com

Virbac acquired Sasaeah, a leading animal health player in Japan

On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species. Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues of about €75 million, of which around 50% from vaccines. With strong footholds in Japan, Sasaeah develops, manufactures and markets a large portfolio of veterinary products targeting both farm animals and companion animals. Virbac will benefit from Sasaeah’s manufacturing sites in Japan and in Vietnam, its R&D capabilities as well as more than 500 passionate and skilled employees. Virbac will be propelled as a leading animal health player in Japan, with an opportunity to leverage these capabilities within the Group. Always working for animal healthAt Virbac, we provide innovative solutions to veterinarians, breeders and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services makes it possible to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and together shaping the future of animal health. Press contacts - Agence Libremullenlowe Keïsha Tema - k.tema@libremullenlowe.fr - + 33 7 63 18 59 03Anne Da Silva Passos - a.dasilvapassos@libremullenlowe.fr - +33 7 60 53 99 28 Attachment Virbac_Sasaeah_April 2, 2024

AcquisitionVaccine

100 Deals associated with Virbac SA

100 Translational Medicine associated with Virbac SA

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 14 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Vaneprim ( TGM2 )	Bacterial Infections More	Discontinued
Crilvastatin ( HMG-CoA reductase )	Hyperlipidemias More	Pending
Triptosine ( 5-HT receptor )	Alcoholism More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Virbac SA

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 14 Nov 2024

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing